CPT® Code 84443

Quick Reference:

• What CPT 84443 means: A quantitative laboratory test for thyroid stimulating hormone (TSH). It reports the analytic service (the lab test), not an office visit or interpretation of imaging.
• When TSH is medically necessary: Medicare recognizes thyroid function testing as reasonable and necessary for evaluating suspected thyroid dysfunction, monitoring known thyroid disease, and in a broad set of clinical contexts where thyroid dysfunction is part of the differential diagnosis (for example, endocrine neoplasms, metabolic disorders, malnutrition, hyperlipidemia, certain anemias, arrhythmias, menstrual disorders, and multiple symptom clusters).
• Medicare frequency baseline: Under CMS NCD 190.22, TSH testing is generally covered up to two times per year in clinically stable patients; more frequent testing may be reasonable and necessary when therapy changes or new symptoms/signs of hyper- or hypothyroidism are present.
• MAC utilization guidance (common outpatient reality): Many Medicare contractors apply utilization guidance that allows thyroid testing (including CPT 84443) up to four times per year for most patients, with specific clinical reasons supporting testing beyond the baseline maximum. LCD language also emphasizes that medical necessity must be demonstrated for each service and patients should not routinely require the maximum.
• Commercial payer medical-necessity framing: Major commercial utilization guidelines treat thyroid function testing (including 84443) as medically necessary when used to evaluate symptoms consistent with thyroid disease, assess/monitor confirmed or suspected thyroid disease, or evaluate thyroid function when risk factors are present; they explicitly state testing is not medically necessary as screening in the absence of risk factors.
• Medicaid managed-care policies commonly mirror CMS logic: Example plan policies list CPT 84443 as part of thyroid function testing and state testing may be covered up to two times per year in a stable patient, with more frequent testing covered when therapy changes or symptoms/signs are documented; policies also warn that testing without approved diagnoses may not be reimbursed.
• Documentation is the payment hinge: Medicare requires documentation showing the ordered/provided test is reasonable and necessary and that the ordering intent and medical necessity are documented in the patient record, consistent with regulatory requirements cited by CMS. The billing entity must be able to produce order/intent and supporting information if requested.
• Repeat same-day testing: If the same clinical lab test must be repeated on the same day to obtain multiple results, CMS billing/coding guidance states to use modifier 91 on the repeat test; modifier 91 must not be used for reruns due to specimen/equipment problems or when a one-time reportable result is all that was required.
• Panel/bundling risk: Payers may bundle component codes into an organ- or disease-oriented panel when documentation shows a panel was ordered/performed, and some policies also reference modifier 91 practices for repeat testing and CLIA-related modifiers (for example, QW when applicable for CLIA-waived tests).

CPT 84443 (TSH) is a high-volume laboratory code with predictable denial drivers. Most payment and audit risk is concentrated in four avoidable problems:

1. ordering TSH as routine screening without documented symptoms or risk factors (in conflict with payer medical-necessity rules),
2. exceeding Medicare frequency baselines without documenting why the patient is unstable or why therapy/symptoms justify repeat testing,
3. insufficient ordering documentation (missing intent, missing rationale, or inability to produce it on request), and
4. repeat/same-day billing without correct modifier logic or without a clinical reason for multiple results.

This 2026-focused guide aligns CPT 84443 reporting with CMS NCD requirements, common contractor utilization guidance, and representative commercial and Medicaid plan rules.

Clinical Definition and Test Scope

CPT 84443 reports a laboratory measurement of thyroid stimulating hormone (TSH). It is a discrete analytic service code for a TSH assay and is used when a clinician orders a quantitative TSH result to evaluate or manage thyroid function.

Operationally, CPT 84443 is billed by the performing laboratory (or the entity billing for the laboratory service, depending on contractual and billing arrangements). The key compliance point is that the claim must reflect a medically necessary diagnostic service rather than a routine wellness add-on, and the medical record must show that the test was ordered (or intent to order is documented) and that the result is relevant to patient management. CMS documentation guidance emphasizes that Medicare pays for medically necessary services and requires documentation demonstrating medical necessity for ordered/provided tests.

Practical boundary: CPT 84443 represents the TSH test itself. Coverage decisions are driven less by the lab method and more by whether the chart supports why the test was needed, and whether repeat testing frequency is justified by patient status or therapy changes under Medicare and payer rules.

Medical Necessity: When TSH Testing Is Covered

Medicare’s national coverage policy recognizes thyroid function testing as reasonable and necessary for defining thyroid hyperfunction, euthyroidism, or hypofunction and for monitoring known thyroid disease. CMS NCD 190.22 also describes a broad set of clinical contexts where thyroid testing may be medically necessary, including thyroid and endocrine neoplasms as well as multiple systemic conditions and symptom complexes where thyroid dysfunction is part of the clinical evaluation.

Commercial medical-necessity frameworks often express the same concept in utilization-management terms: thyroid function testing is medically necessary for evaluation of signs/symptoms consistent with thyroid disease, for assessment/monitoring of confirmed or suspected thyroid disease, or when specific risk factors are present; and not medically necessary as screening in the absence of risk factors.

2.1 Common “covered intent” categories

• Evaluation of suspected thyroid dysfunction: Ordering TSH as part of assessment of symptoms or clinical findings consistent with thyroid disease is an accepted medical-necessity pathway under payer criteria.
• Monitoring established thyroid disease or thyroid therapy: CMS NCD 190.22 explicitly notes follow-up testing may be medically necessary in patients on long-term thyroid drug therapy, and it describes when increased frequency can be reasonable and necessary (for example, after therapy alteration or when symptoms/signs are present).
• Broader differential diagnosis contexts: CMS NCD language includes multiple categories of disease and symptom clusters for which thyroid testing may be medically necessary (for example, endocrine neoplasms and wide arrays of signs and symptoms). Documenting the clinical reasoning within these categories strengthens defensibility.

2.2 What payers commonly treat as “not medically necessary”

A frequent denial scenario is ordering TSH as a routine screening test without symptoms, risk factors, or a documented clinical reason. Commercial utilization guidance explicitly identifies thyroid function testing as not medically necessary when criteria are not met, including as screening in the absence of risk factors.

Audit reality: If the record reads like “routine labs” rather than a clinically motivated evaluation (symptoms, risk factors, suspected/known thyroid disease, therapy monitoring), denials become more likely—especially when frequency is high or when diagnosis coding is non-specific.

Medicare Coverage: NCD 190.22 and Frequency Expectations

Medicare coverage for thyroid testing is anchored in CMS National Coverage Determination (NCD) 190.22. The NCD states thyroid function tests may be reasonable and necessary to define thyroid function status and describes clinical circumstances supporting medical necessity. It also includes a clear utilization limitation: testing may be covered up to two times a year in clinically stable patients, and more frequent testing may be reasonable and necessary when thyroid therapy has been altered or when symptoms/signs of hyperthyroidism or hypothyroidism are noted.

3.1 Translating the NCD into defensible charting

The NCD’s frequency language is not a substitute for medical necessity documentation. Instead, treat it as a baseline expectation that informs how to document:

• Stable patient, routine monitoring: Expect scrutiny if testing exceeds the “up to two times per year” baseline for clinically stable patients without documentation of instability or therapy change.
• Therapy change or symptoms: When increasing frequency, explicitly document what changed (dose adjustment, medication initiation/discontinuation, new symptoms/signs) and how results will affect management.
• Long-term therapy monitoring: CMS notes follow-up testing may be medically necessary in patients on long-term thyroid drug therapy; documenting the treatment context and clinical purpose reduces ambiguity.

MAC/LCD Utilization Guidance and What Auditors Look For

In addition to national coverage policy, Medicare Administrative Contractors (MACs) often publish utilization guidance through Local Coverage Determinations (LCDs). A commonly cited LCD example, LCD L35099 (Frequency of Laboratory Tests), lists thyroid testing (including CPT 84443) with a utilization guideline of four times a year for most patients and provides examples of acceptable reasons for exceeding the LCD maximum (for example, inability to stabilize thyroid medication dosing, thyrotoxicosis, concurrent endocrinopathies, hypothyroidism). The LCD also states Medicare requires medical necessity for each service and expects patients will not routinely require the maximum allowable number of services.

4.1 Reconciling the NCD “2/year” with LCD “4/year” language

In practice, coding and compliance teams should read these policies together:

• NCD sets national coverage concepts and provides an explicit baseline frequency statement for clinically stable patients.
• LCD utilization guidance reflects how contractors operationalize frequency review and appeals, but still requires that each test be medically necessary and supported in the record.

The defensible approach is to treat two per year as the stable baseline, and when testing approaches or exceeds higher utilization guidance thresholds, ensure the documentation clearly supports instability, dose changes, or active clinical management questions.

High-yield compliance note: LCD language explicitly warns that even where Medicare allows up to maximums, the patient’s condition and response to treatment must warrant the number of services reported, and medical necessity must be clearly demonstrated in the medical record. This is a direct signal of what auditors will evaluate.

Medicaid and Commercial Plan Coverage Rules

5.1 Medicaid managed care (example policy behavior)

Medicaid coverage policies vary by state and plan, but many managed-care reimbursement policies closely track Medicare’s medical-necessity narrative and frequency logic. For example, a Medicaid managed-care reimbursement policy explicitly describes thyroid function testing, lists CPT 84443 among covered thyroid tests, and states testing may be covered up to two times per year in a stable patient, with more frequent testing potentially covered when therapy is altered or symptoms/signs are present. The policy also indicates that if the CPT codes are billed without an approved diagnosis, the claim will not be reimbursed.

5.2 Commercial plan utilization management

Commercial payer medical-necessity rules are often expressed as clinical indications. A representative guideline identifies thyroid function testing as medically necessary for: (1) evaluation of signs or symptoms consistent with thyroid disease, (2) evaluation, assessment, or monitoring of confirmed or suspected thyroid disease, or (3) evaluation of thyroid function when risk factors are present; and states testing is not medically necessary when these criteria are not met, including as screening in the absence of risk factors. The guideline also lists CPT codes including 84443 under medically necessary use.

Practically, this means that “screening” intent (for example, ordering TSH as part of routine labs without symptoms/risk factors) increases denial risk in commercial settings, especially if diagnosis coding is non-specific and if documentation does not describe a thyroid-related clinical question.

Documentation Standards for Audit Defense

Documentation expectations for clinical diagnostic laboratory services are a frequent source of denials during record review. CMS guidance emphasizes that Medicare pays for tests that are reasonable and necessary and requires documentation of medical necessity in the patient’s medical record. It also explains that the billing entity must keep documentation, including documentation of the order (or documentation supporting intent to order), and diagnostic or other medical information provided to the lab. CMS further states that while a signature is not required on the physician order for certain clinical diagnostic tests, the physician must clearly document intent to perform the test in the patient’s medical record, consistent with the regulatory standard referenced by CMS.

6.1 Minimum documentation elements (practical, payer-realistic)

• Ordering intent: A documented order, protocol, or chart note demonstrating the clinician intended to order TSH (84443).
• Medical necessity rationale: Symptoms, signs, risk factors, suspected/known thyroid disease, or therapy-monitoring context explaining why TSH is needed and how results will influence management.
• Linkage to patient management: A record that supports the test is being used in the course of treatment (for example, dose adjustment decision-making or evaluation of symptoms). CMS documentation guidance is framed around paying only for medically necessary services ordered and provided.
• Repeat testing justification: When repeating within short intervals, document what changed (therapy alteration, instability, new symptoms) to align with Medicare frequency logic.

6.2 Standing orders and protocols

CMS recognizes that “standing orders” and protocols may exist, but documentation must support that orders are tailored appropriately and that medical necessity is documented and available upon request for claim review. In practical audit defense, avoid a record that appears to be “routine labs by protocol” without member-specific clinical justification.

Audit-proofing rule: If you cannot produce documentation showing intent to order and the medical necessity rationale, the claim becomes difficult to defend even if the TSH result was clinically informative. CMS explicitly frames documentation retention and availability for review as part of compliance.

Frequency Limits, Repeat Testing, and Same-Day Rules

7.1 Routine frequency: stable versus unstable patients

Medicare’s national policy states that testing may be covered up to two times per year in clinically stable patients, with more frequent testing potentially reasonable and necessary when therapy has been altered or when symptoms/signs of thyroid dysfunction are noted.

Contractor utilization guidance may list higher frequency ceilings (for example, up to four times per year for thyroid testing for most patients), but the LCD language explicitly cautions that medical necessity must be demonstrated for each service and that patients should not routinely require the maximum.

7.2 Same-day repeat testing and modifier 91

If the same clinical diagnostic lab test must be repeated on the same day to obtain multiple test results, CMS billing/coding guidance instructs that modifier 91 should be used. The same guidance states modifier 91 may not be used when tests are repeated to confirm initial results due to testing problems with equipment or specimens, or when a normal one-time reportable result was all that was required.

Some payer policies reinforce similar rules: modifier 91 should be appended to claims for repeat testing when clinically required at different times throughout the day and should not be submitted when the test is rerun due to specimen/equipment issues.

7.3 Practical examples of appropriate vs inappropriate repeat billing

• Appropriate: A second TSH is drawn later the same day because the clinician needs multiple results during treatment to guide immediate management decisions (rare in outpatient thyroid management but possible in complex inpatient contexts). The second line uses 84443-91, and the record explains why multiple results were required.
• Inappropriate: The lab reruns the same specimen due to an analyzer or specimen issue. This is not a separately reportable repeat test; modifier 91 is not appropriate because the goal is to obtain a single valid reportable result.

Key takeaway: Use modifier 91 only when the clinical course requires multiple reportable results on the same day. If the rerun is quality-control or error-correction, it is not a separately billable repeat.

Bundling and Panel Logic: How Payers Recode Thyroid-Related Labs

A common payment issue is panel bundling and recoding when multiple tests are billed as components but documentation indicates a panel was ordered and performed. A payer panel billing policy states it reserves the right to bundle individual codes that belong to a panel; if documentation shows a panel was ordered/performed but the claim lists components, the payer may bundle into the appropriate panel code for reimbursement.

8.1 Why this matters for TSH

TSH (84443) is frequently ordered as a single test, but it can also appear as a component within larger panels ordered for general assessment. For example, some organ/disease-oriented panel definitions include TSH as one constituent test (policy examples list panels and constituent tests for billing logic). When a panel code is appropriate and all constituent tests were performed, the policy states the panel code should be billed and the components should not be billed separately.

8.2 Avoidable errors

• Component billing when a panel was ordered and performed: Increases recoding risk and payment variance.
• Multiple overlapping panels billed together: Policies warn not to report two or more panel codes that include the same constituent tests from the same patient collection.
• Repeat testing without correct modifier logic: Some panel billing policies also state modifier 91 should be used for repeat testing throughout the day when required, and that claims may be denied for failure to append modifier 91 or if repeat testing does not meet standard guidelines.

Operational control: Align ordering workflows (single TSH vs thyroid panel vs broader assessment panels) with billing logic and ensure the documentation matches what was performed. Mismatches are a frequent trigger for bundling or downcoding.

Comparison Table and Common Coding Patterns

Real-World Clinical Scenarios

Scenario 1: Stable hypothyroidism monitoring (routine frequency)

Setting: Outpatient primary care.

Clinical situation: Patient with established hypothyroidism on stable levothyroxine dose, no new symptoms.

Coding logic: Bill 84443 for the TSH test when ordered and performed. Frequency beyond the stable baseline is more vulnerable unless the record supports a change in therapy or symptoms/signs.

Documentation tip: Include the management intent (routine monitoring of stable therapy) and ensure the order/intent is documented and retrievable under CMS documentation expectations.

Scenario 2: Dose adjustment or new symptoms (justifying increased frequency)

Setting: Endocrinology follow-up.

Clinical situation: Recent thyroid therapy alteration (dose change) or new symptoms/signs consistent with hyper- or hypothyroidism.

Coding logic: Bill 84443. Medicare NCD language supports more frequent testing when therapy is altered or symptoms/signs are noted.

Documentation tip: Make the “why now” explicit (therapy change date, symptom onset, clinical question) to support medical necessity per-test and reduce frequency denials under LCD expectations.

Scenario 3: Commercial plan denial risk—screening intent without risk factors

Setting: Annual wellness visit with no thyroid-related symptoms or risk factors documented.

Clinical situation: TSH ordered as part of routine screening labs.

Denial risk: Commercial utilization guidance states thyroid function testing is not medically necessary when criteria are not met, including as screening in the absence of risk factors.

Compliance takeaway: If the clinical rationale is not thyroid-related and no risk factors are documented, the safest approach is to avoid representing the service as medically necessary thyroid evaluation.

Scenario 4: Medicaid managed-care policy—diagnosis gating and frequency

Setting: Medicaid managed-care outpatient clinic.

Clinical situation: TSH ordered for thyroid evaluation, but the claim lacks an approved diagnosis per plan policy.

Denial risk: Plan policy indicates that if thyroid testing codes (including 84443) are billed without an approved diagnosis, the claim will not be reimbursed; it also describes a two-per-year baseline in stable patients with allowance for more frequent testing when therapy changes or symptoms/signs are present.

Operational control: Ensure the diagnosis coding on the claim reflects the charted clinical indication and matches plan coverage logic.

Scenario 5: Same-day repeat testing (rare but high-scrutiny)

Setting: Complex clinical course requiring multiple results in a day (most often hospital-based care).

Clinical situation: The same lab test must be repeated on the same day to obtain multiple reportable results.

Coding logic: Bill the first 84443 normally and bill the repeat as 84443-91 when clinically necessary to obtain multiple results; do not use modifier 91 for reruns due to specimen/equipment issues.

Documentation tip: Chart why multiple same-day results were required (the clinical decision point) and retain supporting order/intent documentation consistent with CMS lab documentation requirements.